Detalles de la búsqueda
1.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739457
2.
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
Blood
; 120(4): 858-67, 2012 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22685174
3.
Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians.
Haematologica
; 96(5): 696-702, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21330327
4.
Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned.
Blood Rev
; 50: 100851, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34088518
5.
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.
Am J Blood Res
; 11(4): 417-426, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34540351
6.
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Eur J Haematol
; 85(3): 231-5, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20491881
7.
Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Front Immunol
; 11: 1942, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32983123
8.
Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study.
Ther Adv Hematol
; 11: 2040620720955002, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33101618
9.
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.
Front Pharmacol
; 11: 209, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32210809
10.
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.
Front Pharmacol
; 11: 1308, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33013368
11.
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.
Front Pharmacol
; 11: 571066, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33192513
12.
Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.
Blood Rev
; 34: 16-25, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30448050
13.
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.
J Comp Eff Res
; 8(7): 523-533, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31037971
14.
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Lancet Haematol
; 4(3): e127-e136, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28162984
15.
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Nat Med
; 22(7): 727-34, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27294874
16.
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Cancer Med
; 4(12): 1789-97, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26376955
17.
Costs and quality of life in patients with myelodysplastic syndromes.
Am J Blood Res
; 3(3): 246-59, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23997987
18.
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Leuk Lymphoma
; 54(11): 2458-65, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23432724
19.
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
Cancer Cell
; 24(1): 90-104, 2013 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-23845443
20.
Outcome of therapy-related myeloid neoplasms treated with azacitidine.
J Hematol Oncol
; 5: 44, 2012 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22853048